Editas Medicine Strikes License Deal With Vertex Pharmaceuticals
December 13 2023 - 9:49AM
Dow Jones News
By Dean Seal
Editas Medicine has agreed to license Vertex Pharmaceuticals its
Cas9 gene editing technology for ex vivo gene editing medicines
targeted at sickle cell disease and beta thalassemia.
The clinical-stage genome editing company said Wednesday that
under the terms of the agreement, Vertex will obtain a
non-exclusive license for the technology in medicines targeting the
BCL11A gene in the fields of sickle cell disease and beta
thalassemia, which includes the cell-based gene therapy
Casgevy.
The deal extends Editas' cash runway into 2026, the company
said, though it didn't disclose the financial terms of the
agreement.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 13, 2023 09:34 ET (14:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2024 to May 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From May 2023 to May 2024
